SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
|
Oct 2017
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions: Myelodysplastic Syndromes
|
May 2018
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
|
Nov 2015
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial.
|
Dec 2018
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Prognostic factors and risk models in myelodysplastic syndromes
|
Sep 2013
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes
|
Sep 2013
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes
|
Mar 2019
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
|
Jun 2015
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
|
Jun 2015
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|
Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine.
|
Jun 2013
|
Clin Lymphoma Myeloma Leuk
|
myelodysplastic syndromes (MDS)
|